Skip to content
Menu

Galectin Therapeutics Q3 EPS $(0.04) Beats $(0.05) Estimate

Benzinga Newsdesk 1 day ago

NewsEarningsEarnings Beats

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 69.23 percent increase over losses of $(0.13) per share

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 69.23 percent increase over losses of $(0.13) per share from the same period last year.

Read at benzinga.com